JSPR
Price
$14.76Alerts
Change
+$0.01 (+0.07%)
Updated
Nov 11 closing price
Capitalization
561.01M
118 days until earnings call
Intraday BUY SELL Signals
OCS
Price
$7.61Alerts
Change
+$0.02 (+0.26%)
Updated
Nov 11 closing price
Capitalization
415.9M
131 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JSPR vs OCS

JSPR vs OCS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JSPR vs. OCS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSPR is a Hold and OCS is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for JSPR with price predictions
Nov 10, 2026

Momentum Indicator for JSPR turns negative, indicating new downward trend

JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

JSPR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for JSPR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for JSPR just turned positive on October 23, 2026. Looking at past instances where JSPR's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.

Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for OCS with price predictions
Nov 10, 2026

OCS's RSI Oscillator ascends from oversold territory

The RSI Oscillator for OCS moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 20 of the 24 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 47 cases where OCS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for OCS just turned positive on October 21, 2026. Looking at past instances where OCS's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.

Following a +13.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCS advanced for three days, in 151 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

OCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCS as a result. In 44 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

The Aroon Indicator for OCS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.896) is normal, around the industry mean (3.498). P/E Ratio (-5.428) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
JSPR: Fundamental Ratings
JSPR
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
47

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JSPROCS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
47%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
58%
Advances
ODDS (%)
Bullish Trend 15 days ago
84%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 7 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
66%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
59%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (JSPR: $14.75 vs. OCS: $7.59)
Brand notoriety: JSPR and OCS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JSPR: 248% vs. OCS: 89%
Market capitalization -- JSPR: $561.01M vs. OCS: $415.9M
JSPR [@Biotechnology] is valued at $561.01M. OCS’s [@Biotechnology] market capitalization is $415.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JSPR’s FA Score shows that 0 FA rating(s) are green while OCS’s FA Score has 2 green FA rating(s).

  • JSPR’s FA Score: 0 green, 5 red.
  • OCS’s FA Score: 2 green, 3 red.
According to our system of comparison, OCS is a better buy in the long-term than JSPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JSPR’s TA Score shows that 2 TA indicator(s) are bullish while OCS’s TA Score has 5 bullish TA indicator(s).

  • JSPR’s TA Score: 2 bullish, 5 bearish.
  • OCS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, OCS is a better buy in the short-term than JSPR.

Price Growth

JSPR (@Biotechnology) experienced а +2.43% price change this week, while OCS (@Biotechnology) price change was -0.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

JSPR is expected to report earnings on Mar 09, 2027.

OCS is expected to report earnings on Mar 22, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

OCS and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCS has been loosely correlated with PRAX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then PRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
-2.19%
PRAX - OCS
37%
Loosely correlated
+1.39%
JSPR - OCS
34%
Loosely correlated
-9.90%
FTH - OCS
32%
Poorly correlated
+1.89%
JBIO - OCS
31%
Poorly correlated
+5.13%
CELC - OCS
31%
Poorly correlated
-4.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
PORTAL.X0.0124020.000245
+2.02%
Portal cryptocurrency
IOTA.X0.0345470.000134
+0.39%
IOTA cryptocurrency
LNC42.77-0.21
-0.49%
Lincoln National Corp
MDX.X0.000481-0.000003
-0.65%
Mdex cryptocurrency
SYN.X0.130715-0.006342
-4.63%
Synapse cryptocurrency